Key result
Adding ezetimibe as a second-line treatment for dyslipidemia reduced LDL-C levels by 28.2%, a significantly greater reduction than statin switching or statin doubling.
Why the study?
Does adding ezetimibe, switching statins, or doubling statin dose improve LDL-C reduction in patients with dyslipidemia not at goal on baseline therapy?
Cohort (n=641)
Yes
Does adding ezetimibe, switching statins, or doubling statin dose improve LDL-C reduction in patients with dyslipidemia not at goal on baseline therapy?
Answers are grounded in this paper and cite their sources.
In Japanese patients not at LDL-C goals on baseline therapy, adding ezetimibe provided greater LDL-C reduction than switching or doubling statins, without worsening glycemic control.
Previous studies have shown that approximately 50% patients at risk of cardiovascular disease do not achieve lipid management goals. Thus, improvements dyslipidemia management are needed. We investigated the clinical choice and efficacy of second-line treatments for dyslipidemia in the Japanese clinical setting. Using a retrospective cohort design, we collected lipid profile data from patients who had been treated with hypolipidemic agents at a stable dosage for at least 12 weeks. These patients had then been administered a second-line treatment for dyslipidemia because they had not achieved the low-density lipoprotein cholesterol (LDL-C) management goals. We included data from 641 patients in our analysis. The top three choices for second-line treatment were adding ezetimibe, switching to strong statins (statin switching), and doubling the original statin dosage (statin doubling). Adding ezetimibe, statin switching, and statin doubling decreased LDL-C levels by 28.2 ± 14.5%, 23.2 ± 24.4%, and 23.5 ± 17.2%, respectively. Among these three strategies, adding ezetimibe decreased LDL-C levels to the maximum extent. In patients with dysglycemia, baseline-adjusted change in hemoglobin A1c (HbA1c) levels decreased slightly in the adding-ezetimibe, statin-switching, and statin-doubling groups, but the differences were not statistically significant among the groups (−0.10 ± 0.62%, −0.22 ± 0.54%, and −0.12 ± 0.52%, p = 0.19). In conclusion, the most common second-line treatment options for dyslipidemia were adding ezetimibe, statin switching, or statin doubling. Adding ezetimibe resulted in the highest reduction in LDL-C levels. These strategies did not increase HbA1c levels when administered with conventional diabetes treatment.
No takes yet. Share an insight, caveat, or question.
Kondo et al. (2014) conducted a cohort in Dyslipidemia in patients at risk of cardiovascular disease (n=641). Second-line dyslipidemia treatments (adding ezetimibe, statin switching, statin doubling) vs. Baseline treatment was evaluated on Percentage change in LDL-C levels from baseline (p=<0.001). Adding ezetimibe as a second-line treatment for dyslipidemia reduced LDL-C levels by 28.2%, a significantly greater reduction than statin switching or statin doubling.
Synapse has enriched 10 related papers. Consider them for comparative context: